Skip to content

AMGN Price, Chart & Factor Exposure

Free Data & Analytics Access
AMGN · E.AMGN.NEO · Canada
Use symbol E.AMGN.NEO in our API & Excel add-in to retrieve this data ↓
—
(—)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum —
Trend —
Bubble Risk LOW
Realised Volatility (20D) —

AMGN Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
AMGN
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
AMGN
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
AMGN
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for AMGN, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on AMGN

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

About AMGN (Canada)

AMGN is a listed security in Canada. This page shows the latest price and daily change, a price chart, its factor exposures and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Amgen Inc

Frequently asked questions

What is AMGN?
AMGN is a listed security in Canada. On MacroFinance its page shows the latest price and daily change, a price chart, its factor exposures and free historical data.
What factors affect AMGN?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to AMGN, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Where can I download free AMGN historical data?
In the Free historical data section of this page: the last 10 years of AMGN daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free AMGN historical data (last 10 years)

Browse or instantly download the last 10 years of AMGN daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.AMGN.NEO&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-05-2825.1
2026-05-2725.15
2026-05-2624.99
2026-05-2525.64
2026-05-2225.4
2026-05-2125.07
2026-05-2024.69
2026-05-1924.25
2026-05-1524.3
2026-05-1424.8824
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.